

Opinion & Special Article: Glioma Classification

How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report

Matthijs van der Meulen, MD, PhD, Ronald C. Ramos, MD, Warren P. Mason, MD, Andreas Von Deimling, MD, PhD, and Sybren L.N. Maas, MD, PhD

Neurology® 2022;99:903-908. doi:10.1212/WNL.0000000000201262

Correspondence

Dr. van der Meulen
matthijs.vandermeulen@
mst.nl

Abstract

Diffuse infiltrating gliomas are the most common malignant brain tumors in adults. The 2021 World Health Organization classification for CNS tumors (CNS5 WHO) has significantly altered the rules for classification and grading of diffuse gliomas. Clinicians, including neurology residents and neurologists, will have to consider the changes that include the introduction of new tumor types, allotting established tumor types to other groups and substituting previously essential morphological features for additional molecular markers. For example, in the current classification, glioblastoma is defined as isocitrate dehydrogenase (IDH)-wildtype, grade 4. Whereas, a grade 4 IDH-mutated astrocytic glioma is referred to as astrocytoma, IDH-mutated, grade 4. In addition, potential targeted treatments, based on the underlying molecular alterations, have become therapeutic options for diffuse gliomas. For clinicians, it is important to know the rationale for why these options are only available for specific tumors. Owing to the emphasis of molecular markers in the CNS5 WHO classification, interpretation of a pathology report and understanding of its clinical implications can be challenging. This review describes the most important molecular alterations in glioma, summarizes the recent changes in the CNS5 WHO classification for glioma, and presents a stepwise approach for trainees and neurologists to decipher a glioma pathology report. Additional information is summarized in eTable 1 (links.lww.com/WNL/C324).

From the Departments of Neurology and Medical Oncology and Hematology (M.v.d.M., R.C.R., W.P.M.), Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada; Department of Neurology (M.v.d.M.), Medisch Spectrum Twente, Enschede, the Netherlands; Division of Neurology (R.C.R.), Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Neuropathology (A.V.D.), University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg; Department of Pathology (S.L.N.M.), University Medical Center, Utrecht; and Department of Pathology (S.L.N.M.), Leiden University Medical Center, the Netherlands.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

In adult patients, diffuse infiltrating gliomas are the most common malignant primary brain tumors.¹ After publication of the 2016 World Health Organization (WHO) classification of tumors of the CNS,² the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy—not officially WHO published summaries concerning evolving concepts in the biology of glioma and their prognostic implications.³ In 2021, these summaries served as the basis for the updated WHO CNS (CNS5) classification (Figure 1).⁴

Because molecular alterations became increasingly important in the classification and grading of brain tumors, the interpretation of a pathology report can be challenging for clinicians new to the field of neuro-oncology. Because neuro-oncology is not part of the curriculum for all neurology residents in the United States and Europe,^{5,6} we provide an overview of the most important molecular features in glioma including their diagnostic, prognostic, and potential therapeutic roles (Figure 1 and eTable 1, links.lww.com/WNL/C324).

Histology

Histologic tissue evaluation is central and the first step in the diagnostic process (Figure 2). Much of the basis for classification and grading of diffuse glioma can be obtained by assessment of differentiation status, cell density, mitotic activity, the presence or absence of necrosis, and/or microvascular proliferation. In addition to classical histology, several immunohistochemical markers provide direct information on essential molecular parameters such as IDH1-R132H, H3, and ATRX status. However, classification and grading of many diffuse gliomas demand additional molecular analyses as a second step (Figure 2).

IDH

Hotspot mutations in isocitrate dehydrogenase (IDH) enzymes facilitate the production of 2-hydroxyglutarate, which leads to competitive inhibition of alpha-ketoglutarate-dependent enzyme activity, resulting in distinct epigenetic histone and DNA modification, followed by metabolic reprogramming.⁷ This effect can be mediated by mutations in both the *IDH1* and *IDH2* genes. IDH mutations are considered early driver mutations and are now the basis of molecular glioma classification. The IDH status constitutes a fundamental divide with IDH-mutant astrocytoma and oligodendroglioma on one side and glioblastoma and some rare diffuse gliomas on the other side (Figure 1). A consequence of this central divide among diffuse gliomas has been renaming the formerly IDH-mutant glioblastoma to the current astrocytoma, IDH-mutant, WHO grade 4. The term glioblastoma, a glioma with the worst clinical prognosis, is reserved exclusively for IDH-wildtype grade 4 glioma.

Approximately 90% of the supratentorial IDH mutations are of the IDH1-R132H type, and this can be detected with a

mutation-specific antibody (immunohistochemistry). Other IDH1 (R132C, R132L, R132S) or IDH2 (R172G, R172K, R172M) mutations require DNA sequencing for detection. In patients older than 55 years with a supratentorial tumor, IDH mutations are rare. Therefore, when no IDH1-R132H mutation is found, additional sequencing is required only for patients aged 55 years or younger.⁷ Non-IDH1-R132H mutations constitute roughly 80% of IDH alterations in infratentorial IDH-mutant astrocytoma.⁸

1p/19q

Oligodendrogliomas have, by definition, an IDH mutation and a second molecular alteration that defines the entity: the combined full losses of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), better known as a 1p/19q codeletion. The exact role of the 1p/19q loss in the tumor biology is currently unclear. Of special importance here is that the 1p/19q status is decisive for the separation of astrocytoma from oligodendroglioma (both IDH-mutant) and that morphological aspects are second in relevance.

ATRX

The ATP-dependent X-linked helicase (*ATRX*) gene encodes for a protein involved with telomerase activity. Mutations in *ATRX*, immunohistochemically identified as loss of nuclear expression of this protein, are next to mutually exclusive with 1p/19q loss (oligodendrogliomas). Therefore, loss of nuclear *ATRX* expression can be used as surrogate marker for IDH-mutated astrocytoma. When an IDH mutation is present, it eliminates the need for further 1p/19q testing.³


TP53

TP53, a tumor suppressor gene, is mutated in the majority of grade 2, 3, and 4 IDH-mutated astrocytomas. Strong staining of p53 protein suggests a *TP53* mutation; however, this has a lower specificity than loss of *ATRX* expression for the diagnosis of an astrocytoma.

CDKN2A/B

In IDH-mutated astrocytoma, the cyclin-dependent kinase inhibitor 2A/B (*CDKN2A/B*) status is an important prognostic factor because homozygous deletion of *CDKN2A/B* is associated with increased aggressiveness. Homozygous *CDKN2A/B* loss overrules the histologic grade, so even without microvascular proliferation and/or necrosis, the histologic criteria for a grade 4 tumor, homozygous *CDKN2A/B* loss also warrants a grade 4 diagnosis in IDH-mutated astrocytomas.⁹ Owing to the prognostic significant implications of *CDKN2A/B*, IDH-mutant astrocytoma without 1p/19q codeletion should therefore always be tested for homozygous *CDKN2A/B* loss.

Figure 1 Algorithm for the Classification of Diffuse Gliomas in Adults



The first step is to check the histology of a tissue specimen whether it is compatible with a diffuse tumor of glial origin. Next is to assess by immunohistochemistry for the presence of an IDH mutation and/or loss of nuclear ATRX. A negative result for an IDH1-R132H mutation warrants further testing by DNA sequencing to exclude noncanonical IDH mutations in patients younger than 55 years. An IDH-mutant astrocytoma with a homozygous deletion of CDKN2A/B automatically yields a grade 4 even if there is no necrosis and/or microvascular proliferation. Similarly, an IDH-wildtype astrocytoma without necrosis and/or microvascular proliferation warrants further testing for an EGFR amplification, +7/−10, and/or TERT promoter mutation as the presence of at least one of these molecular features yields a diagnosis of glioblastoma, IDH-wildtype, grade 4. ATRX = ATP-dependent X-linked helicase; CDKN2A/B = cyclin-dependent kinase inhibitor 2A/B; EGFR = epidermal growth factor receptor; IDH = isocitrate dehydrogenase; TERT = telomerase reverse transcriptase.

EGFR Amplification, +7/−10, and/or TERT Promotor Mutation

Three different molecular markers independently warrant the diagnosis of a grade 4 glioblastoma in IDH-wildtype diffuse gliomas because they are associated with very poor clinical outcome:

1. Epidermal growth factor receptor (EGFR) amplification.
2. The complete gain of chromosome 7 in combination with a complete loss of chromosome 10, often referred to as +7/−10. It is unclear whether tumors harboring variants of +7/−10 (e.g., +7p/−10 or +7/−10q) are as aggressive as tumors with the full +7/−10 loss.¹⁰
3. Mutations in the promotor of the telomerase reverse transcriptase (*TERT*) gene. TERT promoter mutations lead to the reactivation of telomerase, resulting in maintained telomere length and thus limitless cellular lifespan.

Thus, in an IDH-wildtype astrocytoma without microvascular proliferation and/or necrosis, the histologic criteria for a grade 4 tumor, testing for these alterations is important because of the prognostic and possible therapeutic consequences. Overall, TERT mutations in this triad of markers are most


sensitive but least specific, while both EGFR mutation and +7/−10 signature have high specificity with lower sensitivity. Very frequently, these alterations occur together, and the presence of any 2 of the 3 features is highly specific for glioblastoma. TERT promoter mutations do also occur in tumors within the differential diagnosis of glioblastoma such as pleomorphic xanthoastrocytoma. Furthermore, these mutations occur in most oligodendrogliomas.

H3 K27M and H3 G34

Two diffuse glioma entities have histone 3 (H3) alterations. Both are rare, IDH-wildtype, and have an aggressive course (grade 4). These tumors occur most often in children and young adults. Diffuse midline gliomas, H3 K27–altered, are gliomas with H3 K27-trimethylation alterations (H3F3A/B K27M mutation being most common), are located in midline CNS structures (i.e., brainstem, thalamus, or spinal cord), and have a diffuse infiltrative growth pattern.³ The presence of all criteria is important because H3 K27M can also be found in other entities that may have different pathogenesis and prognosis.

Diffuse gliomas that feature H3 G34 mutations are located most often in a supratentorial hemisphere and can have a nonenhancing

Figure 2 Stepwise Approach and Timeline of the Diagnostic Process



In clinical practice, information regarding the studied material becomes available in a stepwise manner. First, the material is studied using microscopic techniques. This includes the analysis of morphological features (e.g., cell atypia, mitotic activity, necrosis, and/or vascular proliferations) supplemented in most cases by immunohistochemical stains to investigate the presence of specific (mutated) proteins (e.g., ATRX, p53, and/or IDH-R132H). This first step of the investigation takes up to 1–3 working days to come up with a histologic diagnosis that is then shared with the clinicians. In most cases, a second step featuring molecular investigations is needed to arrive at the integrated diagnosis. The method picked is determined by the histologic diagnosis. In morphological glioblastoma cases in patients older than 55 years with a negative IDH1-R132H immunohistochemical analysis, it requires only testing for MGMT promoter status. For other cases, NGS and/or methylation profiling using the brain tumor classifier will also be required to investigate specific molecular markers. Depending on local protocols and the technique used, information regarding the methylation class, chromosomal gains, losses, amplifications, and/or specific mutations can be obtained. With the required information on the presence or absence of an IDH mutation, TERT promoter mutation, 1p/19q codeletion, EGFR amplification, +7/–10, and a CDKN2A/B homozygous loss, the final integrated diagnosis based on the histologic diagnosis and molecular alterations can be rendered. Sometimes, the required techniques are initiated in parallel, but when inconclusive results are obtained or when limited material is available, the techniques can also be initiated subsequently, delaying the rendering of an integrated diagnosis. Note: the times listed are only an estimation and can differ based on local protocols. In addition, because the analyses are performed in batches, further delays can be introduced in the case of low sample counts and/or infrequent analysis runs. ATRX = ATP-dependent X-linked helicase; CDKN2A/B = cyclin-dependent kinase inhibitor 2A/B; EGFR = epidermal growth factor receptor; IDH = isocitrate dehydrogenase; MGMT = O6-methylguanine-DNA methyl-transferase; NGS = next-generation sequencing; TERT = telomerase reverse transcriptase.

appearance on MRI. These tumors are termed diffuse hemispheric glioma, H3 G34–mutant. H3-mutated gliomas have a prognosis similar to that of glioblastoma, IDH-wildtype.^{11,12}

MGMT

Hypermethylation of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter leads to reduced expression of this DNA repair protein. MGMT repairs the damage by alkylating chemotherapeutic agents, rendering the tumor more resistant to alkylating chemotherapy.¹³ MGMT promoter methylation status is a biomarker of both prognostic and therapeutic significance in glioblastoma, IDH-wildtype. Glioblastoma with MGMT promoter hypermethylation have a better prognosis and more favorable response to chemotherapy (eTable 1, [links.lww.com/WNL/C324](https://www.lww.com/WNL/C324)).¹⁴

FGFR1/NF1/BRAF

The RAS/mitogen-activated protein kinase (MAPK) pathway plays an important role in cell regulation, including proliferation and differentiation. Although MAPK-pathway alterations occur most often in pediatric low-grade gliomas, they are also observed in adult diffuse gliomas. Several gene alterations can lead to an upregulation of this pathway. Genes involved with this pathway include fibroblast growth factor receptor 1 (FGFR1), neurofibromin 1 (NF1, affected in

neurofibromatosis type 1), and BRAF.¹⁵ The most common MAPK pathway alteration is a BRAF p.V600E mutation that occurs in approximately 2% of adult glioblastoma cases. The exact incidence of BRAF fusions, FGFR, and other MAPK alterations remains to be determined as novel techniques to detect them become more widely available.⁴ For some MAPK-activating alterations, antagonistic therapeutic options are available (eTable 1, [links.lww.com/WNL/C324](https://www.lww.com/WNL/C324)).

Methylation Brain Tumor Classifier

In recent years, methylation patterns generated by genome-wide DNA methylation profiling have been increasingly used to assist tumor diagnosis for their potential to predict specific tumor types. Methylation profiling requires a classification tool for tumor class prediction, a calibrated score for the validity of the prediction, and a copy number profile. The methylation-based approach has been used for the identification of many novel brain tumor entities (e.g., high-grade astrocytoma with piloid features). Methylation analysis is a powerful emerging diagnostic tool, and its use is encouraged for all diagnostically unresolved brain tumor samples.

NOS/NEC

In some cases, molecular testing is not performed or interpretable because of sparse resources or for intentional reasons (e.g., no therapeutic consequences). In those cases,

the term “not otherwise specified (NOS)” should be added to the histologic diagnosis: for example, astrocytoma, WHO grade 2, NOS (note: no IDH status listed).

In the event that molecular testing was performed and valid results were obtained, but the results did not lead to a CNS5-compatible diagnosis, the term “not elsewhere classified (NEC)” should be added to the diagnosis. For example, a nondiffuse hemispheric glioma with a K27M mutation results in nondiffuse nonmidline K27-altered glioma, NEC.³

Relevance to Neurologists and Trainees

Molecular alterations have become increasingly important in the diagnosis and classification of glioma. For many entities, specific molecular alterations are required to render a WHO CNS5-compatible diagnosis.

In clinical practice, information regarding the studied material becomes available in a step-wise manner (Figure 2). This has resulted in a layered integrated diagnosis starting with a histopathologic classification days after surgery. The histopathologic findings are used to select subsequent molecular testing. For example, in histologic low-grade diffuse glioma, it is important to determine the IDH status and the presence of specific markers that determine the diagnosis (e.g., 1p/19q codeletion for oligodendroglioma) or grade (homozygous CDKN2A/B loss for astrocytoma) (Figure 1 and eTable1, links.lww.com/WNL/C324). This additional information is added to the report, after which the integrated diagnosis is rendered. Alterations that can have potential therapeutic consequences (e.g., MGMT promotor methylation) will be listed under the “molecular alterations” layer.

For example:

Integrated diagnosis: astrocytoma, IDH-mutant, WHO CNS5 grade 2

Histopathologic classification: low-grade diffuse glioma
CNS5 WHO grade: 2

Molecular information: IDH1-R132H–mutated, ATRX mutation, TP53 mutation, no CDKN2A/B loss, no 1p/19q codeletion

Acknowledgment

M. van der Meulen received a travel grant from the Dr. Jan Meerwaldt foundation.

Study Funding

No targeted funding reported.

Disclosure

The authors report no relevant disclosures. Go to [Neurology.org/N](https://www.neurology.org) for full disclosures.

Publication History

Received by *Neurology* December 2, 2021. Accepted in final form August 1, 2022. Submitted and externally peer reviewed. The handling editors were Whitley Aamodt, MD, MPH, and Roy Strowd III, MD, MEd, MS.

Appendix Authors

Name	Location	Contribution
Matthijs van der Meulen, MD, PhD	Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada; Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
Ronald C. Ramos, MD	Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; Division of Neurology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data
Warren P. Mason, MD	Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data
Andreas Von Deimling, MD, PhD	Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data
Sybrene L.N. Maas, MD, PhD	Department of Pathology, Leiden University Medical Center, the Netherlands; Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data

References

- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. *Neuro Oncol*. 2020;22(12 suppl 2):iv1-iv96.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. *World Health Organization Histological Classification of Tumours of the Central Nervous System*. 4th ed. International Agency for Research on Cancer, 2016.
- Gonzalez Castro LN, Wesseling P. The cIMPACT-NOW updates and their significance to current neuro-oncology practice. *Neurooncol Pract*. 2021;8(1):4-10.
- WHO Classification of Tumours Editorial Board. *World Health Organization Classification of Tumours of the Central Nervous System*. 5th ed. International Agency for Research on Cancer, 2021.
- Johnson NE, Maas MB, Coleman M, Jozefowicz R, Engstrom J. Education research: neurology training reassessed. The 2011 American Academy of Neurology Resident Survey results. *Neurology*. 2012;79(17):1831-1834.
- Kleineberg NN, van der Meulen M, Franke C, et al. Differences in neurology residency training programmes across Europe—a survey among the Residents and

- Research Fellow Section of the European Academy of Neurology national representatives. *Eur J Neurol.* 2020;28(8):1356-1363.
7. Chen L, Voronovich Z, Clark K, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. *Neuro Oncol.* 2014;16(11):1478-1483.
 8. Banan R, Stichel D, Bleck A, et al. Infiltrantorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathol.* 2020;140(4):569-581.
 9. Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol.* 2018;136(1):153-166.
 10. Stichel D, Ebrahimi A, Reuss D, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathol.* 2018;136(5):793-803.
 11. Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. *Neuro Oncol.* 2017;19(8):1127-1134.
 12. Picart T, Barritault M, Poncet D, et al. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. *Neurooncol Adv.* 2021;3(1):vdab061.
 13. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature.* 2012;483(7390):479-483.
 14. Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. *Neuro Oncol.* 2019;21(2):167-178.
 15. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. *Proc Natl Acad Sci USA.* 2013;110(15):5957-5962.

The *Neurology*[®] Null Hypothesis Online Collection...

Contributing to a transparent research reporting culture!



The *Neurology* journals have partnered with the Center for Biomedical Research Transparency (CBMRT) to promote and facilitate transparent reporting of biomedical research by ensuring that all biomedical results—including negative and inconclusive results—are accessible to researchers and clinicians in the interests of full transparency and research efficiency.

Neurology's Null Hypothesis Collection is a dedicated online section for well conducted negative, inconclusive, or replication studies. View the collection at: NPub.org/NullHypothesis



Without Borders – A curated collection featuring advances in global neurology

This *Neurology*[®] special interest website is the go-to source for tracking science and politics of neurology beyond the United States, featuring up-to-the-minute blogs, scholarly perspectives, and academic review of developments and research from *Neurology* journals and other sources.

Expand your world view at Neurology.org/woborders.

Neurology®

Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report

Matthijs van der Meulen, Ronald C. Ramos, Warren P. Mason, et al.
Neurology 2022;99:903-908 Published Online before print September 2, 2022
DOI 10.1212/WNL.0000000000201262

This information is current as of September 2, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/99/20/903.full
References	This article cites 13 articles, 2 of which you can access for free at: http://n.neurology.org/content/99/20/903.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Education http://n.neurology.org/cgi/collection/all_education Primary brain tumor http://n.neurology.org/cgi/collection/primary_brain_tumor
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

